Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

592
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
592
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiobjective starfish optimization algorithm for engineering design and optimal power flow problems.

Scientific reports·2026
Same author

A CASE OF REFRACTORY IRON DEFICIENCY ANEMIA REVEALING HEREDITARY HEMORRHAGIC TELANGIECTASIA.

Georgian medical news·2026
Same author

ACANTHOSIS NIGRICANS, OBESITY, AND DIABETES RISK FACTORS: A COMMUNITY-BASED MULTICENTER STUDY IN QASSIM, SAUDI ARABIA.

Georgian medical news·2026
Same author

Multi attribute group decision-making based on quasirung orthopair fuzzy Frank aggregation operators for optimal vehicle selection.

Scientific reports·2025
Same author

Effect of lactation on postpartum pelvic floor muscle regeneration in preclinical model.

npj women's health·2025
Same author

MCGDM approach based on (p, q, r)-spherical fuzzy Frank aggregation operators: applications in the categorization of renewable energy sources.

Scientific reports·2024

Related Experiment Video

Updated: Apr 7, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

7.2K

Micro- and Nanoparticles for Treating Cardiovascular Disease.

S Suarez1, A Almutairi2, K L Christman1

  • 1Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, California, United States.

Biomaterials Science
|July 7, 2015
PubMed
Summary

Micro- and nano-particle therapies show promise for treating cardiovascular diseases like myocardial infarction (MI) and peripheral artery disease (PAD) by delivering therapeutic agents to injured tissues.

More Related Videos

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

Related Experiment Videos

Last Updated: Apr 7, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

7.2K
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Cardiovascular Research

Background:

  • Cardiovascular diseases, such as myocardial infarction (MI) and peripheral artery disease (PAD), affect millions, with current treatments inadequately restoring blood flow or repairing ischemic damage.
  • Vessel occlusion leads to ischemic injury in the heart and skeletal muscle, necessitating advanced therapeutic strategies.

Purpose of the Study:

  • To review existing particle-based therapies for treating myocardial infarction (MI) and peripheral artery disease (PAD).
  • To explore the potential of micro- and nano-particles as delivery vehicles for therapeutic agents in cardiovascular disease treatment.

Main Methods:

  • Review of current literature on particle-based therapies for MI and PAD.
  • Analysis of micro- and nano-particle formulations and their delivery mechanisms (direct injection vs. intravenous).

Main Results:

  • Micro- and nano-particles are being developed as delivery systems for growth factors, enzymes, and small molecules.
  • These particles offer sustained therapeutic stimulus at injury sites.
  • Particle formulations allow for targeted delivery via direct injection or accumulation after intravenous administration.

Conclusions:

  • Particle-based therapies represent a promising approach to address the limitations of current treatments for MI and PAD.
  • Further development of micro- and nano-particle delivery systems could significantly improve outcomes for patients with cardiovascular diseases.